{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:51:09Z","timestamp":1788609069948,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clinre.2026.102827","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:34:48Z","timestamp":1776011688000},"page":"102827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety and efficacy of everolimus as a rescue therapy in autoimmune hepatitis"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3637-6855","authenticated-orcid":false,"given":"Florian","family":"Seltsam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Konstantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Guckenbiehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut H.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Veltkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clinre.2026.102827_bib0001","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jaut.2004.11.009","article-title":"Clinical features and biochemical data of Caucasian children at diagnosis of autoimmune hepatitis","volume":"24","author":"Oettinger","year":"2005","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.clinre.2026.102827_bib0002","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/hep.24080","article-title":"Autoimmune acute liver failure: proposed clinical and histological criteria","volume":"53","author":"Stravitz","year":"2011","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.clinre.2026.102827_bib0003","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jhep.2021.12.041","article-title":"Systematic review of response criteria and endpoints in autoimmune hepatitis by the international autoimmune hepatitis group","volume":"76","author":"Pape","year":"2022","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.clinre.2026.102827_bib0004","first-page":"769","article-title":"Adverse effects of azathioprine in the treatment of inflammatory bowel disease","volume":"93","author":"Mart\u00ednez","year":"2001","journal-title":"Rev Esp Enferm Dig"},{"issue":"10","key":"10.1016\/j.clinre.2026.102827_bib0005","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1155\/2010\/891252","article-title":"Mycophenolate mofetil for the treatment of autoimmune Hepatitis in patients refractory or intolerant to conventional therapy","volume":"24","author":"Sharzehi","year":"2010","journal-title":"Canadian J Gastroenterol"},{"issue":"6","key":"10.1016\/j.clinre.2026.102827_bib0006","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jhep.2020.07.023","article-title":"Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European reference network on hepatological diseases and the international autoimmune hepatitis group","volume":"73","author":"Lohse","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2026.102827_bib0007","doi-asserted-by":"crossref","DOI":"10.1007\/s12094-024-03839-0","article-title":"Azathioprine and risk of non-melanoma skin cancers in organ transplant recipients: a systematic review and update meta-analysis","author":"Kreuz","year":"2025","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102827_bib0008","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s41598-023-50602-6","article-title":"Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis","volume":"14","author":"Lim","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.clinre.2026.102827_bib0009","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/jgh.14533","article-title":"Risk of skin cancers in thiopurines-treated and thiopurines-untreated patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"34","author":"Huang","year":"2019","journal-title":"J Gastro Hepatol"},{"issue":"6","key":"10.1016\/j.clinre.2026.102827_bib0010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/jlts.2001.24645","article-title":"MTOR inhibitors: an overview","volume":"7","author":"Neuhaus","year":"2001","journal-title":"Liver Transplant"},{"issue":"17","key":"10.1016\/j.clinre.2026.102827_bib0011","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1056\/NEJMoa1100391","article-title":"Efficacy and safety of sirolimus in lymphangioleiomyomatosis","volume":"364","author":"McCormack","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clinre.2026.102827_bib0012","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1634\/theoncologist.2009-0178","article-title":"FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma","volume":"15","author":"Kwitkowski","year":"2010","journal-title":"Oncologist"},{"issue":"33","key":"10.1016\/j.clinre.2026.102827_bib0013","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.21.01728","article-title":"nab -Sirolimus for patients with malignant perivascular epithelioid cell tumors","volume":"39","author":"Wagner","year":"2021","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.clinre.2026.102827_bib0014","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1074\/jbc.270.2.815","article-title":"Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells","volume":"270","author":"Sabers","year":"1995","journal-title":"J Biologic Chem"},{"key":"10.1016\/j.clinre.2026.102827_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.663602","article-title":"Conversion from Calcineurin inhibitors to mammalian target of rapamycin inhibitors in kidney transplant recipients: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Zeng","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.clinre.2026.102827_bib0016","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40272-024-00648-4","article-title":"Role of mTOR inhibitors in pediatric liver transplant recipients: a systematic review","volume":"26","author":"Moghadamnia","year":"2024","journal-title":"Pediatr Drugs"},{"issue":"1","key":"10.1016\/j.clinre.2026.102827_bib0017","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/ijd.14549","article-title":"Mammalian target of rapamycin (mTOR) inhibitors and skin cancer risk in nonrenal solid organ transplant recipients: systematic review and meta-analysis","volume":"59","author":"Phan","year":"2020","journal-title":"Int J Dermatol"},{"issue":"8","key":"10.1016\/j.clinre.2026.102827_bib0018","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/ndt\/gfw088","article-title":"Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients","volume":"31","author":"Opelz","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.clinre.2026.102827_bib0019","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clinre.2026.102827_bib0020","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3109\/00365521.2014.998271","article-title":"Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use","volume":"50","author":"Ytting","year":"2015","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1016\/j.clinre.2026.102827_bib0021","doi-asserted-by":"crossref","DOI":"10.1097\/PG9.0000000000000227","article-title":"Everolimus is safe as a second-\/third-line therapy in pediatric autoimmune Hepatitis","volume":"3","author":"Jannone","year":"2022","journal-title":"JPGN Report"},{"key":"10.1016\/j.clinre.2026.102827_bib0022","article-title":"EASL clinical practice guidelines on the management of autoimmune hepatitis","author":"Gatselis","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2026.102827_bib0023","doi-asserted-by":"crossref","DOI":"10.1097\/MPG.0b013e318291feaa","article-title":"Sirolimus as rescue therapy in pediatric autoimmune hepatitis","volume":"58","author":"Kurowski","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.clinre.2026.102827_bib0024","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s10620-015-4022-0","article-title":"Refractory autoimmune hepatitis: beyond standard therapy","volume":"61","author":"Rubin","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"11","key":"10.1016\/j.clinre.2026.102827_bib0025","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.amjmed.2014.06.016","article-title":"Use of Sirolimus in the treatment of refractory autoimmune Hepatitis","volume":"127","author":"Chatrath","year":"2014","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.clinre.2026.102827_bib0026","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1007\/s12094-024-03839-0","article-title":"Azathioprine and risk of non-melanoma skin cancers in organ transplant recipients: a systematic review and update meta-analysis","volume":"27","author":"Kreuz","year":"2025","journal-title":"Clin Transl Oncol"},{"issue":"9","key":"10.1016\/j.clinre.2026.102827_bib0027","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1007\/s00403-023-02646-x","article-title":"A review of heart transplant immunosuppressants and nonmelanoma skin cancer","volume":"315","author":"Eckembrecher","year":"2023","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"10.1016\/j.clinre.2026.102827_bib0028","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14207","article-title":"Comparison of two strategies based on mammalian target of rapamycin inhibitors in secondary prevention of non-melanoma skin cancer after kidney transplantation, a pilot study","volume":"35","author":"Pr\u00e9terre","year":"2021","journal-title":"Clin Transplant"},{"key":"10.1016\/j.clinre.2026.102827_bib0029","article-title":"European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: diagnostics and prevention\u2013Update 2023","volume":"193","author":"Stratigos","year":"2023","journal-title":"Eur J Cancer"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126000744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740126000744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:26:05Z","timestamp":1780529165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740126000744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2210740126000744"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102827","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of everolimus as a rescue therapy in autoimmune hepatitis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2026.102827","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102827"}}